Rising Pharma Demand Prompts CRO Covance to Fortify its Protein Biomarker Business | GenomeWeb

This story originally ran on Dec. 2.

By Tony Fong

Increasing demand for its protein biomarker services has prompted Covance to ramp up its biomarker operations.

Last month, the Princeton, NJ-based contract research organization announced it had made Rules Based Medicine its exclusive third-party provider of multiplexed protein biomarker testing services. In return, the Austin, Texas biomarker testing laboratory will use Covance as its exclusive referral source for laboratory-based tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.